{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:22:59Z","timestamp":1788906179929,"version":"build-2803163510"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,10]],"date-time":"2015-09-10T00:00:00Z","timestamp":1441843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Sanofi US, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,12]]},"abstract":"\n Insulin glargine 100\u2009units\/ml (\n Gla\u2010100<\/jats:styled-content>\n ) has become a standard of care in diabetes treatment over the past decade, providing 24\u2010h basal insulin coverage after once\u2010daily subcutaneous injection for many people with diabetes, with a well\u2010established efficacy and safety profile. New insulin glargine 300\u2009units\/ml (\n Gla\u2010300<\/jats:styled-content>\n ) is a basal insulin that provides the same number of units as\n Gla\u2010100<\/jats:styled-content>\n in a third of the volume. Compared with\n Gla\u2010100<\/jats:styled-content>\n ,\n Gla\u2010300<\/jats:styled-content>\n has shown more constant and prolonged pharmacokinetic (\n PK<\/jats:styled-content>\n )\/pharmacodynamic (\n PD<\/jats:styled-content>\n ) profiles. This review summarizes the findings from the\n EDITION<\/jats:styled-content>\n series of clinical trials that investigated\n Gla\u2010300<\/jats:styled-content>\n in individuals with type 1 and type 2 diabetes mellitus. Overall,\n Gla\u2010300<\/jats:styled-content>\n has been shown to achieve similar glycaemic control with less, or similar, nocturnal hypoglycaemia compared with\n Gla\u2010100<\/jats:styled-content>\n , and a trend towards lower hypoglycaemia at any time of day. The\n EDITION<\/jats:styled-content>\n series of clinical trials also provides some evidence for less weight gain with\n Gla\u2010300<\/jats:styled-content>\n than with\n Gla\u2010100<\/jats:styled-content>\n . In addition, the\n PK<\/jats:styled-content>\n \/\n PD<\/jats:styled-content>\n profiles of\n Gla\u2010300<\/jats:styled-content>\n may allow more flexibility in the timing of doses, improving convenience; thus,\n Gla\u2010300<\/jats:styled-content>\n could offer several positive features for individuals with diabetes requiring basal insulin therapy.\n <\/jats:p>","DOI":"10.1111\/dom.12531","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T11:59:42Z","timestamp":1435924782000},"page":"1107-1114","source":"Crossref","is-referenced-by-count":17,"title":["A review of the safety and efficacy data for insulin glargine 300\u2009units\/ml, a new formulation of insulin glargine"],"prefix":"10.1111","volume":"17","author":[{"given":"G.","family":"Dailey","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism Scripps Clinic La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lavernia","sequence":"additional","affiliation":[{"name":"North Broward Diabetes Center Coconut Creek FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,9,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902775677"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","article-title":"New insulin glargine 300 units\u00b7mL\u20101 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units\u00b7mL\u20101","volume":"38","author":"Becker RH","year":"2014","journal-title":"Diabetes Care"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2004.6.698"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12283"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12416"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12415"},{"key":"e_1_2_8_8_1","first-page":"S388","article-title":"Insulin glargine 300 U\/ml vs 100 U\/ml: glucose profiles of morning vs evening injections in adults with type 1 diabetes mellitus measured with continuous glucose monitoring (CGM) [abstract P949]","volume":"57","author":"Bergenstal RM","year":"2014","journal-title":"Diabetologia"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0991"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12472"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0990"},{"key":"e_1_2_8_12_1","first-page":"S387","article-title":"Less nocturnal hypoglycaemia and weight gain with new insulin glargine 300 U\/ml vs 100 U\/ml: 1\u2010year results in people with type 2 diabetes using basal insulin\u2009+\u2009OADs (EDITION 2) [abstract 946]","volume":"57","author":"Yki\u2010J\u00e4rvinen H","year":"2014","journal-title":"Diabetologia"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12438"},{"key":"e_1_2_8_14_1","first-page":"LB19","article-title":"Glycemic control and hypoglycemia with new insulin glargine 300U\/mL in people with T1DM (EDITION 4) [abstract 80\u2010LB]","volume":"63","author":"Home PD","year":"2014","journal-title":"Diabetes"},{"key":"e_1_2_8_15_1","first-page":"LB22","article-title":"New insulin glargine 300 U\/mL: glycemic control and hypoglycemia in Japanese people with T1DM (EDITION JP 1) [abstract 88\u2010LB]","volume":"63","author":"Matsuhisa M","year":"2014","journal-title":"Diabetes"},{"key":"e_1_2_8_16_1","first-page":"LB24","article-title":"Glycemic control and hypoglycemia in Japanese people with T2DM receiving new insulin glargine 300 U\/mL in combination with OADs (EDITION JP 2) [abstract 94\u2010LB]","volume":"63","author":"Terauchi Y","year":"2014","journal-title":"Diabetes"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2480"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12485"},{"key":"e_1_2_8_19_1","first-page":"S393","article-title":"New insulin glargine 300 U\/ml: efficacy and safety of flexible vs fixed dosing intervals in people with type 2 diabetes mellitus [abstract 961]","volume":"57","author":"Jeandidier N","year":"2014","journal-title":"Diabetologia"},{"key":"e_1_2_8_20_1","unstructured":"Toujeo (insulin glargine injection) U\u2010300. Prescribing information; revised 2015 February. Available from URL:www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206538lbl.pdf. Accessed 13 August 2015."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12222"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01638.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01627.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12032"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP13287.OR"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0096-7"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP13411.OR"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0067"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12223"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2621"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12531","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:07:46Z","timestamp":1761862066000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,10]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1111\/dom.12531"],"URL":"https:\/\/doi.org\/10.1111\/dom.12531","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,10]]}}}